NASDAQ:PROG
Delisted
Progenity, Inc. Stock News
$0.94
-0.0340 (-3.48%)
At Close: Aug 17, 2022
Progenity Provides Financial Guidance for Full-year 2021
04:05pm, Wednesday, 13'th Jan 2021
Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million
Progenity to Present at the 2021 ICR Conference
07:30am, Tuesday, 05'th Jan 2021
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
07:30am, Thursday, 17'th Dec 2020
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity Announces Closing of Public Offering of Common Stock
07:30am, Tuesday, 08'th Dec 2020
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mo
Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering
11:51pm, Wednesday, 02'nd Dec 2020
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes du
Progenity Announces Pricing of Public Offering of Common Stock
11:50pm, Wednesday, 02'nd Dec 2020
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mo
Progenity Announces Proposed Convertible Senior Notes Offering
09:39pm, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of co
Progenity Announces Proposed Public Offering of Common Stock
09:38pm, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mol
High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of
Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
07:30am, Tuesday, 17'th Nov 2020
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference
07:30am, Monday, 16'th Nov 2020
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
07:30am, Friday, 13'th Nov 2020
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript
10:30pm, Monday, 09'th Nov 2020
Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
